Why Tim O’Rourke’s Arrival and Fresh Guidance Matter for agilon health Stock

The recent appointment of Tim O’Rourke as CEO of agilon health (AGL), alongside better-than-expected first-quarter results and higher full-year sales guidance, puts fresh attention on how this value-based care company is repositioning its business.

agilon health’s 1 day share price return of 7.22% came after the CEO announcement and guidance update, capping a very large 90 day gain and strong year to date momentum, although the 3 year total shareholder return remains sharply negative.

If this kind of sharp move has your attention, it could be a good moment to look at other healthcare focused opportunities using the 34 healthcare AI stocks.

With agilon health trading at $86.39, well above the average analyst price target of $55.46 yet showing a large intrinsic discount estimate, investors are left with a key question: is there still a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 339.2% Overvalued

At a last close of $86.39 against a narrative fair value of $19.67, agilon health’s current price sits far above this widely followed view, which leans heavily on long term cash flow and margin assumptions.

The analysts have a consensus price target of $19.67 for agilon health based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $37.5, and the most bearish reporting a price target of just $6.25.

Want to understand why a business with ongoing losses still attracts a double digit fair value per share? Revenue assumptions, margin rebuild and future earnings multiples all sit at the core of this narrative, and the balance between them is not obvious from headline numbers alone.

Result: Fair Value of $19.67 (OVERVALUED)

However, ongoing net losses of US$373.543m and execution risk around payer contract renegotiations could still unsettle expectations and put pressure on the bullish narrative.

Another Way to Look at agilon health’s Value

The analyst narrative points to a fair value of $19.67 and labels agilon health as overvalued, but the SWS DCF model paints a very different picture, with a future cash flow value estimate of $356.38. When one model implies overvaluation and another suggests a large discount, which set of assumptions feels more reasonable to you?

Next Steps

With sentiment clearly mixed in this article, it makes sense to review the underlying data yourself and act promptly to form your own view using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If agilon health has you thinking harder about risk, reward and timing, it is worth widening your search and lining up a few high quality alternatives.

• Target higher quality at a reasonable price by scanning for companies that combine solid fundamentals with attractive valuations using the 48 high quality undervalued stocks.
• Prioritise resilience first and see which stocks clear strict balance sheet and earnings filters with the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by reviewing a curated screener containing 21 high quality undiscovered gems before other investors catch on.

Skip guesswork and start building a watchlist of fresh ideas today, otherwise you risk missing opportunities that better fit your goals and risk comfort.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.